Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.

A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget (2013) 1.27

The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal (2012) 0.90

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget (2014) 0.89

Glioblastoma chemotherapy adjunct via potent serotonin receptor-7 inhibition using currently marketed high-affinity antipsychotic medicines. Br J Pharmacol (2010) 0.88

The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses (2005) 1.53

Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget (2012) 1.22

Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother (2006) 1.20

Crohn's disease remission on bupropion. Gastroenterology (2003) 0.92

Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol (2011) 0.90

Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol (2008) 0.90

Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol (2007) 0.87

Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther (2013) 0.87

Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation (2010) 0.85

Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. Int J Oncol (2011) 0.85

Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer (2009) 0.84

How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett (2006) 0.83

Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion. J Hepatol (2003) 0.83

Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anticancer Agents Med Chem (2014) 0.82

Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha. J Rheumatol (2008) 0.82

Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha? Psychosom Med (2003) 0.80

Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses (2005) 0.80

Erlotinib in glioblastoma: lost in translation? Anticancer Agents Med Chem (2011) 0.80

Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis. Med Hypotheses (2005) 0.79

Ritonavir and disulfiram have potential to inhibit caspase-1 mediated inflammation and reduce neurological sequelae after minor blast exposure. Med Hypotheses (2008) 0.78

Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.76

Bupropion and chronic aphthous ulceration. Arch Dermatol (2005) 0.76

Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry (2006) 0.76

H1-antihistamines. N Engl J Med (2005) 0.75

Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists. Neoplasia (2007) 0.75

Bupropion for Blau syndrome. Med Hypotheses (2004) 0.75

Regulatory effect of chemokines in bone marrow niche. Cell Tissue Res (2015) 0.75

Intraperitoneal lavage with imiquimod to eliminate epithelial ovarian cancer micro metastases. Med Hypotheses (2008) 0.75

Paroxetine for hepatopulmonary syndrome? Med Hypotheses (2004) 0.75

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells: consideration of triamterene to treat lupus. Med Hypotheses (2010) 0.75

Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy. Kidney Int (2005) 0.75